Innovation Series: Advanced Science (ISSN 2938-9933, CNKI Indexed)

Volume 3 · Issue 10 (2026)
90
views
DOI number:
10.66521/2938-9933-2026101902

Analysis of Breast Cancer Burden Trends in China (1990–2021) Using the GBD Database

 

Liting Yang1,*, Ting Wei1, Yao He2

1 Nanchong Central Hospital/The second Clinical Medical College of North Sichuan Medical College, Nanchong, China

2 Shuangqiao Town Health Center, Nanchong, China

Corresponding Author: Liting Yang

 

Abstract: Objective: To gain a comprehensive understanding of the long-term evolutionary patterns and gender disparities in breast cancer burden in China from 1990 to 2021, and to explore the association between the Age-Standardized Incidence Rate (ASIR) and the Socio-Demographic Index (SDI), so as to provide a scientific basis for formulating targeted prevention and control strategies.
Methods: Based on the 2021 Global Burden of Disease (GBD) dataset, four core indicators of breast cancer were extracted: number of deaths, Disability-Adjusted Life Years (DALYs), prevalence cases, and incidence cases. Descriptive statistics were used to analyze the distribution characteristics of indicators stratified by gender. The Joinpoint regression model was applied to calculate the Average Annual Percent Change (AAPC) and analyze the temporal trend of indicators. Pearson correlation analysis was conducted to examine the correlation between ASIR and SDI.
Results: From 1990 to 2021, the overall burden of breast cancer in China showed a significant upward trend, with the largest increase in prevalence (366.40%), followed by incidence (364.50%). The growth rate and annual average growth rate of all disease burden indicators in males were higher than those in females, while females accounted for the vast majority of the absolute disease burden. The age-standardized rates showed a fluctuating upward trend. Projections indicated that the female ASIR would continue to rise from 2021 to 2040 and remain much higher than that of males. There were significant regional differences in the incidence and prevalence of breast cancer worldwide, with obvious geographical clustering characteristics. ASIR was significantly positively correlated with SDI (r = 0.767, P < 0.001).
Conclusion: The burden of breast cancer in China continues to increase, posing an increasingly severe challenge to the healthcare system. Among them, the male disease burden grows rapidly and requires targeted attention. The levels of disease prevention and control vary significantly across regions. There is an urgent need to develop differentiated prevention and control strategies combining gender characteristics and regional epidemiological features to address this increasingly prominent public health issue.

 

Keywords: Breast cancer; Disease burden; Gender difference; Socio-Demographic Index; Age-standardized incidence rate 
 

References

[1]
Lan T, Gao W, Chen L, et al. Global, regional, national burden and risk factors in female breast cancer from 1990 to 2021. iScience. 2024;27(8):111045. PMID:39435147
[2]
Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229‑263. PMID:38638278
[3]
Li T, Mello‑Thoms C, Brennan PC. Descriptive epidemiology of breast cancer in China: incidence, mortality, survival and prevalence. Breast Cancer Res Treat. 2016;159(3):395‑406. PMID:27510477
[4]
Britt KL, Cuzick J, Phillips KA. Key steps for effective breast cancer prevention. Nat Rev Cancer. 2020;20(8):417‑436. PMID:32601339
[5]
Zhang Q, Liu H. Demographic transition and cancer burden among Chinese population: evidence from national surveillance data. J Epidemiol Glob Health. 2023;13(4):567‑576. PMID:38128741
[6]
Chen X, Li Y. Clinical‑epidemiologic profile of male breast cancer in East‑Asian populations: pooled observational analysis. Asian J Androl. 2022;24(6):589‑595. PMID:35443261
[7]
Deng T, He J, Li M, et al. Global, Regional, and National Burden of Breast Cancer, 1990‑2021, and Projections to 2050: A Systematic Analysis of the Global Burden of Disease Study 2021. Thorac Cancer. 2025;16(9):e70052. PMID:39942101
[8]
Zhou Y, Wang X. Spatial‑temporal patterns of female breast cancer burden across mainland China, 1990‑2021: sub‑national analysis from GBD 2021. BMC Public Health. 2025;25(1):412. PMID:40087213
[9]
GBD 2021 Risk Factors Collaborators. Global burden of 88 risk factors in 204 countries and territories, 1990‑2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403(10440):2143‑2196. PMID:38603039
[10]
Anderson BO, Ilbawi AM, El Saghir NS. Breast cancer in low and middle income countries (LMICs): a shifting tide in global health. Breast J. 2015;21(1):111‑118. PMID:25470803
[11]
Gucalp A, Traina TA. Male breast cancer: epidemiology, biology, and therapeutic approaches. J Clin Oncol. 2021;39(21):2373‑2384. PMID:34185541
[12]
Lyu G, Shao Y. The features of male breast cancer in China: A real‑world study. Breast. 2024;74:103762. PMID:38924994
Download PDF
Innovation Series

Innovation Series is an academic publisher publishing journals and books covering a wide range of academic disciplines.

Contact

Francesc Boix i Campo, 7

08038 Barcelona, Spain